Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Investing Activities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash from Investing Activities for 3 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 1760.46% to $16.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.4 million, a 152.64% increase, with the full-year FY2025 number at $63.4 million, up 152.64% from a year prior.
  • Cash from Investing Activities was $16.0 million for Q4 2025 at Artiva Biotherapeutics, down from $16.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $21.1 million in Q2 2025 to a low of -$130.6 million in Q3 2024.
  • A 3-year average of -$6.0 million and a median of $5.6 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 26396.55% in 2024, then surged 1760.46% in 2025.
  • Artiva Biotherapeutics' Cash from Investing Activities stood at -$2.7 million in 2023, then surged by 63.79% to -$966000.0 in 2024, then soared by 1760.46% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Cash from Investing Activities are $16.0 million (Q4 2025), $16.3 million (Q3 2025), and $21.1 million (Q2 2025).